Amelioration of Motor Performance and Nigrostriatal Dopamine Cell Volume Using a Novel Far-Infrared Ceramic Blanket in an A53T Alpha-Synuclein Transgenic Parkinson’s Disease Mouse Model DOI Creative Commons
Frederick Robert Carrick, Luis Sebástian Alexis Valerio, Kimio Sugaya

et al.

Current Issues in Molecular Biology, Journal Year: 2023, Volume and Issue: 45(12), P. 9823 - 9837

Published: Dec. 6, 2023

We had attended a Parkinson’s Disease (PD) patient for non-healing wound who reported marked decrease in his hand tremor and freezing of gait when was exposed to ceramic far-field infrared (cFIR) blanket. PD is the most frequent motor disorder second neurodegenerative disease after Alzheimer’s (AD). The tremor, rigidity, slowness movement associated with affect up 10 million people throughout world, major contributing factor pathogenesis accumulation propagation pathological α-synuclein (α-Syn) death dopaminergic cells Nigrostriatal system. Efforts slow or stop its spreading have resulted development use drug replacement therapy. Unfortunately, there loss about 70–80% substantia nigral neurons patients by time they are diagnosed PD, various drugs provide only temporary relief their symptoms. There limitations treating many conventional medications, necessitating combination pharmaceutical non-pharmacological therapy as an essential adjunct better address health welfare patients. used male adult A53T alpha-synuclein transgenic mice far-infrared Motor activity assessed using rotarod apparatus, mouse brains were examined quantify fluorescence intensities immunostained samples. significantly shorter stay on rotating bar than wild-type (B6C3H). performance improved cFIR well B6C3H healthy wild cFIR. significant statistical substantive increase cellular composition Striatum nigra cFIR-treated mice. Improvement seen increases cell volume striatum treatment.

Language: Английский

Amelioration of Motor Performance and Nigrostriatal Dopamine Cell Volume Using a Novel Far-Infrared Ceramic Blanket in an A53T Alpha-Synuclein Transgenic Parkinson’s Disease Mouse Model DOI Creative Commons
Frederick Robert Carrick, Luis Sebástian Alexis Valerio, Kimio Sugaya

et al.

Current Issues in Molecular Biology, Journal Year: 2023, Volume and Issue: 45(12), P. 9823 - 9837

Published: Dec. 6, 2023

We had attended a Parkinson’s Disease (PD) patient for non-healing wound who reported marked decrease in his hand tremor and freezing of gait when was exposed to ceramic far-field infrared (cFIR) blanket. PD is the most frequent motor disorder second neurodegenerative disease after Alzheimer’s (AD). The tremor, rigidity, slowness movement associated with affect up 10 million people throughout world, major contributing factor pathogenesis accumulation propagation pathological α-synuclein (α-Syn) death dopaminergic cells Nigrostriatal system. Efforts slow or stop its spreading have resulted development use drug replacement therapy. Unfortunately, there loss about 70–80% substantia nigral neurons patients by time they are diagnosed PD, various drugs provide only temporary relief their symptoms. There limitations treating many conventional medications, necessitating combination pharmaceutical non-pharmacological therapy as an essential adjunct better address health welfare patients. used male adult A53T alpha-synuclein transgenic mice far-infrared Motor activity assessed using rotarod apparatus, mouse brains were examined quantify fluorescence intensities immunostained samples. significantly shorter stay on rotating bar than wild-type (B6C3H). performance improved cFIR well B6C3H healthy wild cFIR. significant statistical substantive increase cellular composition Striatum nigra cFIR-treated mice. Improvement seen increases cell volume striatum treatment.

Language: Английский

Citations

0